Axsome Therapeutics, Inc.AXSM
Price (close)
$195.09
Market cap
$10.2B
P/E
—
Revenue (TTM)
$776.6M
Net income
-$191.6M
Dividend yield
—
1-year total return
68.2%
Net margin
-24.7%
Revenue growth
56.9%
Debt / equity
2.26x
What Axsome Therapeutics, Inc. does.
No business description on file yet.
Revenue and profit, by fiscal year.
| Fiscal year | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| Revenue | — | — | $0 | $270.6M | $385.7M | $638.5M |
| Net income | -$102.9M | -$130.4M | -$187.1M | -$239.2M | -$287.2M | -$183.2M |
| Free cash flow | -$78.5M | -$108.5M | -$117.2M | -$145.7M | -$128.7M | -$93.9M |
More on AXSM.
- Axsome Therapeutics, Inc. summary
- Axsome Therapeutics, Inc. financial statements
- Axsome Therapeutics, Inc. key metrics
- Axsome Therapeutics, Inc. health scores and style box
- Axsome Therapeutics, Inc. earnings
- Axsome Therapeutics, Inc. dividends
- Axsome Therapeutics, Inc. valuation
- Axsome Therapeutics, Inc. ownership and insiders
- Axsome Therapeutics, Inc. peers
Figures from Axsome Therapeutics, Inc.'s filings with the U.S. SEC, standardised automatically; prices are end-of-day closes. Not financial advice.